论文部分内容阅读
本文介绍用苯巴比妥及其钠盐对人体的直肠吸收速度的研究。通过测定苯巴比妥微型灌肠剂和油脂性栓剂直肠吸收后的血药浓度与口服苯巴比妥钠水溶液比较,得出相对生物利用度。供试剂型口服溶液剂:含苯巴比妥钠219毫克的水溶液200毫升。微型灌肠剂:①溶液剂:含苯巴比妥钠219毫克的0.5％甲基纤维素400cP水溶液20毫升,pH为9.3;②混悬剂:苯巴比妥200毫克(<20微米)混悬在0.5％甲基纤维素400cP水溶液20毫升中,pH为6.3。栓剂:含苯巴比妥钠219毫克的Witepsol H 15栓剂及含苯巴比妥200毫克的Witepsol H 15栓剂。每粒3克,在冰箱中至少放置一夜后使用。体内试验:6个健康受试者交叉试验,给药后0.5、1.0、2.0、3.0、4.0、5.0和6.5小
This article describes the use of phenobarbital and its sodium salt on the rectal absorption rate of the human body. The relative bioavailability was determined by comparing the rectal absorption plasma concentrations of phenobarbital mini-ointment and oleaginous suppository with oral phenobarbital sodium aqueous solution. For oral solution of reagent: 200 ml of aqueous solution containing sodium phenobarbital 219 mg. Micro enema: ① solution: containing 219 mg of phenobarbital sodium 0.5% methyl cellulose 400cP 20 ml of aqueous solution, pH 9.3; ② suspension: phenobarbital 200 mg (<20 microns) suspension The pH was 6.3 in 20 ml of 0.5% methyl cellulose 400 cP aqueous solution. Suppositories: Witepsol H 15 suppository containing phenobarbital at 219 mg and Witepsol H 15 suppository at 200 mg containing phenobarbital. 3 grams each, used in refrigerator for at least one night. In Vivo Assay: Six healthy subjects were crossed with 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.5 post-dose